Celgene meldet ermutigende Testergebnisse mit REVLIMID - 500 Beiträge pro Seite

[Nachrichten [wO]]

Das Biopharma-Unternehmen Celgene Corp. stellte ermutigende klinische Daten zu seinem Medikament REVLIMID vor.

Demnach zeigte das Präparat in einer Phase-II-Studie potenzielle neue Ansätzen bei der Behandlung von Patienten mit rezidivierender oder refraktärer chronischer lymphatischer Leukämie (CLL). Von vierzehn Patienten sprachen alle mit einer Stabilisierung der Krankheit oder besseren Ergebnissen an. Nun nimmt das Unternehmen die nötigen Vorbereitungen für die regulatorischen Strategien für CLL in Angriff.

REVLIMID zählt zu einer Klasse neuartiger immunmodulatorischerMedikamente und wirkt auf mehrere biologische intrazelluläre Mechanismen.

Bisher stiegen die Aktien an der NASDAQ um 2,74 Prozent und stehen derzeit bei 41,07 Dollar.

Wertpapiere des Artikels:
CELGENE CORPORATION


Autor: SmartHouseMedia (© wallstreet:online AG / SmartHouse Media GmbH),16:20 07.06.2005

[midgbridg]

Celgene Added to the Nasdaq-100 Index



- Effective Prior to Market Open on Tuesday, July 5, 2005 -
SUMMIT, N.J., June 24 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG), a leading global biopharmaceutical company, announced that it will be added to the Nasdaq-100 Index(R), effective prior to market open on Tuesday, July 5, 2005. Shares of CELG will also be included in the Nasdaq-100 Index Tracking Stock (Nasdaq: QQQQ).

"Our addition to the Nasdaq-100 Index is a result of the outstanding performance of all of our employees in building Celgene into a leading biopharmaceutical company. This acknowledgement is reflective of both the Company`s strong performance to date, and our potential as we look forward to a promising future," said John W. Jackson, Celgene Chairman and CEO.

Launched in January 1985, the Nasdaq-100 Index represents the largest non- financial domestic and international issues listed on The Nasdaq Stock Market based on market capitalization. The Nasdaq-100 Index Tracking Stock was launched in March 1999 and represents ownership in the Nasdaq-100 Trust. The Trust holds a portfolio of equity securities that compose the Nasdaq-100 Index and aims to provide investment results that generally correspond with the Nasdaq-100 Index performance.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company`s website at http://www.celgene.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company`s control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company`s filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.

SOURCE Celgene Corporation
-0- 06/24/2005 R
/CONTACT: Robert J. Hugin, Senior VP and CFO, [phone], or Brian
P. Gill, Director PR-IR, [phone], both of Celgene Corporation/
/Web site: http://www.celgene.com /
(CELG QQQQ)

CO: Celgene Corporation
ST: New Jersey, New York
IN: BIO MTC FIN HEA
SU:

R
-- NYF065A --
7656 06/27/200507:30 EDThttp://www.prnewswire.com